 PRA Health Sciences selected for the study which will position Awakn at the Forefront of Psychedelic Research for Addiction TreatmentToronto, Ontario--Newsfile Corp. - January 15, 2021 - Awakn Life Sciences announced today the selection of contract research organization CRO, PRA Health Sciences NASDAQ: PRAH, to conduct a Phase IIb trial studying the effectiveness of MDMA-Assisted Psychotherapy as a treatment for patients with Non-Physically Dependent Harmful Use Alcohol Use Disorder AUD.Awakns Phase IIb study will take place in the United Kingdom and will be a double-blind, placebo-controlled clinical trial designed to investigate the safety and... 